$XTALPI(02228.HK) The meeting had two key points: 1. This conference adopted a "1 + 5" model, focusing on the release of provincial-level AI support policies, recommendations for 4 important products, 23 typical "AI +" application cases, etc. Jingtai Technology, as one of the four representative benchmark companies, shared important products and technological achievements alongside companies like Huawei and Tencent. Dr. Ma Jian, Co-founder and CEO, was invited to speak on-site. 2. The world's first pan-TEAD inhibitor, SIGX 2649, has completed preclinical research and is about to submit IND clinical applications simultaneously to Chinese and US regulatory agencies. The entire process of this new drug, from target discovery to candidate compound determination, was deeply empowered by AI, significantly improving R&D efficiency and success rate. Dr. Ma Jian pointed out: "This is not only a breakthrough in single new drug R&D, but also a milestone for AI technology moving from theoretical concept to industrial implementation in the biopharmaceutical field." Summary: As one of the four invited companies, sharing the stage with Huawei and Tencent; 2. Welcoming the milestone of industrial implementation.